Market Overview

Biotech and Cannabis Firms to Watch as Acquisition, Investment, and Licensing Season Begins


Biotech and Cannabis Firms to Watch as Acquisition, Investment, and Licensing Season Begins

PR Newswire

LAS VEGAS, August 16, 2018 /PRNewswire/ --

FN Media Group Presents News Commentary 

Investors have been rushing into Biotech and CBD stocks ahead of potential acquisitions, investments, and licensing deals. Canopy Growth receiving interest from giants like Constellation Brand has the Cannabis sector buzzing. Constellation first announced their interest in the company last October, and just pledged another $5 Billion to the company this week. Biotechnology firms are receiving a lot of attention as well with smaller biotech companies being the ones driving innovation, and there are several Biotech conferences coming up later in the year. These conferences are the battling ground for small and mid size biotech companies looking to grow to the next level.

Here's a few companies you can watch this coming Fall and Winter: BioRestorative Therapies, Inc. (OTC:BRTX), CV Sciences, Inc. (OTC:CVSI), 22nd Century Group, Inc. (NYSE:XXII), Tilray, Inc. (NASDAQ:TLRY), and Aphria Inc. (OTC:APHQF).

BioRestorative Therapies, Inc. (OTCQB:BRTX)

Market Cap: $16.09M Share Price: $2.34 

BioRestorative Therapies, Inc. (BRTX), a life sciences company focused on stem cell-based therapies, just announced that the Journal of Translational Medicine has published the results of the Company's study evaluating the benefits of long-term hypoxic (low oxygen) culturing of human bone marrow-derived mesenchymal stem cells (cells used in the Company's product, BRTX-100). The study included data on cell fitness and whole genome expression and discussed its implication on cellular therapies targeting intervertebral discs and its microenvironment. The FDA has authorized BioRestorative to commence a Phase 2 clinical trial using hypoxic cultured bone marrow-derived mesenchymal stem cells in its lead candidate, BRTX-100, to treat chronic lower back pain.BRTX is on an uptrend over the last two weeks.

CV Sciences, Inc. (OTCQB:CVSI)

Market Cap: $469.63M Share Price: $5.18 

CV Sciences (CVSI) has received more positive attention after it announced that it had appointed Joseph Maroon, MD, FACS to its Board of Directors. The Nevada-based company operates two distinct business segments: a drug development division focused on developing and commercializing novel therapeutics utilizing synthetic CBD, and a consumer product division focused on manufacturing, marketing and selling plant-based CBD products to a range of market sectors. The company's stock is up significantly over the last couple of weeks.

Aphria Inc. (OTCQB:APHQF)

Market Cap: $1.74B, current share price: $7.68 

Aphria Inc., is one of Canada's lowest cost producers, produces, supplies and sells medical cannabis. Located in Leamington, Ontario, the greenhouse capital of Canada. Aphria is truly powered by sunlight, allowing for the most natural growing conditions available. We are committed to providing pharma-grade medical cannabis, superior patient care while balancing patient economics and returns to shareholders.

Tilray, Inc. (NASDAQ:TLRY)

Market Cap: 2.73B, current share price: $29.77 

Tilray, Inc. IPO'd on Thursday July, 19th, at around $20 per share. Shares then spiked at a high of just over $34 a share, before declining in recent sessions to end trading today at $25.36. Tilray, Inc. is a vertically-integrated and federally-licensed cannabis cultivator, processor and distributor. On July 23rd the company announced the closing of it's IPO, and full exercise of the underwriters' option to purchase additional shares.

22nd Century Group, Inc. (NYSE:XXII)

Market Cap: $299.74M Share Price: $2.41 

22nd Century Group, Inc. (XXII), a plant biotechnology company that is focused on tobacco harm reduction, Very Low Nicotine tobacco, and hemp/cannabis research, announced today the Company's second quarter 2018 financial results. With net sales revenue of more than $6.9 million, 22nd Century posted another record quarter. At the same time, 22nd Century significantly increased spending - to more than $2.7 million this quarter - on the Company's Modified Risk Tobacco Product ("MRTP") application to the U.S. Food and Drug Administration ("FDA") for "BRAND A" Very Low Nicotine cigarettes.

For Full Legal Disclaimer Click Here.

Contact Information:

Company Name: Microcap Speculators

Contact Person: Media Manager


Phone: 1-702-720-6310

Country: United States


DISCLAIMER: (MS) is the source of the content set forth above. References to any issuer other than the profiled issuer are intended solely to identify industry participants and do not constitute an endorsement of any issuer and do not constitute a comparison to the profiled issuer. FN Media Group (FNM,) and its online brand, is a third-party publisher and news dissemination service provider, which disseminates electronic information through multiple online media channels. FNM is NOT affiliated with MS or any company mentioned herein. The commentary, views and opinions expressed in this release by MS are solely those of MS and are not shared by and do not reflect in any manner the views or opinions of FNM. Readers of this Article and content agree that they cannot and will not seek to hold liable MS and FNM for any investment decisions by their readers or subscribers. MS and FNM and their respective affiliated companies are a news dissemination and financial marketing solutions provider and are NOT registered broker-dealers/analysts/investment advisers, hold no investment licenses and may NOT sell, offer to sell or offer to buy any security. Investors are cautioned that they may lose all or a portion of their investment when investing in stocks included herein by MS. FNM was not compensated by any public company mentioned herein to disseminate this press release on behalf of MS.

MS Disclosure: Except for the historical information presented herein, matters discussed in this article contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. ACR Communication, LLC, which owns, is not registered with Finra or any other financial or securities regulatory authority, and does not provide nor claims to provide investment advice or recommendations to readers of this release. ACR Communication, LLC [and/or] does not have a position in the securities mentioned herein and may increase or decrease such positions without notice. For making specific investment decisions, readers should seek their own advice. ACR Communication LLC, which owns, is compensated for its services in the form of cash-based compensation or in equity in the companies it writes about, or a combination of the two. ACR Communication, LLC has been compensated one thousand dollars cash for this article and thirteen thousand dollars total by Regal Consulting. LLC, for news commentary articles for BRTX. BRTX and Regal Consulting, LLC were given an opportunity to edit information included in this article. This article is based solely on public information and the opinions of ACR Communication, LLC, which believes the news commentary to include accurate and complete information. ACR Communication, LLC, will not buy or sell any shares in stocks contained within this article for forty eight hours after this article's distribution.

This release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. "Forward-looking statements" describe future expectations, plans, results, or strategies and are generally preceded by words such as "may", "future", "plan" or "planned", "will" or "should", "expected," "anticipates", "draft", "eventually" or "projected". You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a company's annual report on Form 10-K or 10-KSB and other filings made by such company with the Securities and Exchange Commission. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and MS and FNM undertake no obligation to update such statements.

Media Contact

FN Media Group LLC




View Comments and Join the Discussion!